[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1996, Volume 26, Number 1, Page(s) 25-33
[ Summary ]
High frequency audiometry and auditory brain stem response in ototoxicity of cisplatinum
SEMHA BERBEROĞLU1, BİLGEHAN BÖKE2, MÜNEVVER BÜYÜKPAMUKÇU1, FAİK SARIALİOĞLU1, CANAN AKYÜZ1, EROL BELGİN2
Departments of 1Pediatric Oncology, Hacettepe University Institute of Oncology and 2Ear-Nose-Throat, Audiology and Speech Pathology Section, Hacettepe University Medical School, Ankara-Turkey

This study was designed to determine the audiologic effects of cisplatinum (CDDP) in a population of pediatric patients and to evaluate the relative effectiveness of auditory brain stem response (ABR) and high and extra high frequency audiometry. Twenty-five patients and 10 age-matched controls were evaluated. Fifteen children and adolescents, ages ranging from 10 months to 15 years receiving CDDP for the treatment of solid tumors underwent ABR audiometry before therapy and following each dose. Six of these children also underwent high frequency audiometry following each dose. Another group of 10 children, ages 8 to 19 years who had completed CDDP therapy at least 2 years ago underwent high frequency audiometry. Median total dose of CDDP was 600 mg/m2 in 3 to 9 cycles in the first group. In the group who completed therapy, median total dose was 720 mg/m2 in 6 to 12 cycles. A 5 to 30 dB high frequency threshold shift beginning from 12 kHz to 18 kHz was evident after a cumulative CDDP dose of 300 mg/m2. With increasing cumulative dose, median hearing loss was greater at higher frequencies (p<0.05). No correlation between ABR audiometry and high frequency audiometry results could be detected. ABR has limited diagnostic value, for CDDP ototoxicity. Sensitivity of high frequency audiometry is higher compared to ABR. Audiologic monitoring with high frequency audiometry should be performed before therapy, repeated after each dose, particularly following a cumulative dose of 300 mg/m2.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]